NCT01431937View on ClinicalTrials.gov

Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 10, 2010

Primary Completion Date

March 29, 2011

Study Completion Date

March 29, 2011

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

GSK2018682

Active Drug

DRUG

Placebo

Placebo

Trial Locations (3)

2031

GSK Investigational Site, Randwick

5000

GSK Investigational Site, Adelaide

6009

GSK Investigational Site, Nedlands

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01431937 - Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers | Biotech Hunter | Biotech Hunter